FDA approves Xtandi extended indications
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Astellas and Pfizer(http://announced that the U.SFDA(http://approves Xtandi (enzalutamide) to extend the indications to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC)About Xtandi
Xtandi is a specific androgen receptor inhibitor that not only blocks androgen stake-receptor binding, but also inhibits receptor-to-intracellular transfer, as well as androgen receptor-DNA bindingSo it's not just an antagonists for androgen receptors, it also inhibits androgen signaling pathwaysTheof the Phase 3 ClinicalTrial(http:// known as ARCHES showed that xtandi and ADT combined reduced the risk of radiology progression or death in patients by 61% compared to a combination of placebo and androgen deprivation therapy (ADT) (HR-0.39)95% CI: 0.30-0.50, p 0.0001at the same time, the prostate-specific antigen (PSA) in more patients in the Xtandi-ADT treatment group was reduced to a level that could not bedetection(http:// (p0.001).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
